Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last A$0.32 AUD
Change Today -0.015 / -4.48%
Volume 138.0K
As of 12:01 AM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

ellex medical lasers ltd (ELX) Snapshot

Open
A$0.34
Previous Close
A$0.34
Day High
A$0.34
Day Low
A$0.32
52 Week High
01/29/15 - A$0.40
52 Week Low
12/18/14 - A$0.23
Market Cap
34.4M
Average Volume 10 Days
181.9K
EPS TTM
A$0.01
Shares Outstanding
107.6M
EX-Date
12/3/02
P/E TM
28.3x
Dividend
--
Dividend Yield
--
Current Stock Chart for ELLEX MEDICAL LASERS LTD (ELX)

Related News

No related news articles were found.

ellex medical lasers ltd (ELX) Related Businessweek News

No Related Businessweek News Found

ellex medical lasers ltd (ELX) Details

Ellex Medical Lasers Limited designs, manufactures, markets, and sells lasers and ultrasound systems for ophthalmologists to diagnose and treat eye diseases. The company offers selective laser trabeculoplasty (SLT)/YAG combination laser systems for the SLT treatment in glaucoma patients under the Tango and Solo names: iTRACK 250 microcatheter for the treatment of open-angle glaucoma; and Ultra Q Reflex, a multi-modality YAG laser with intraocular lenses (IOL), peripheral iridotomy for glaucoma, and YAG laser vitreolysis for the treatment of floaters. It also provides capsulotomy Ultra Q Reflex multi-modality YAG laser for the treatment of vitreous strands and opacities; Ultra Q, a microsurgical YAG laser for IOL-friendly photodisruption; and Super Q, a YAG laser to correct myopia or hyperopia. In addition, the company offers photocoagulators, including Solitaire, a portable green laser for the treatment of retinal disease; Integre Pro, a laser for use in the diagnosis and treatment of retinal disease; and Rapide, a pattern scanning photocoagulator. Further, it provides Eye Cubed, a diagnostic ultrasound system for the posterior and anterior segments of an eye. Additionally, the company is developing Retinal Rejuvenation Therapy, a non-thermal laser therapy for the treatment of diabetic retinopathy and age-related macular degeneration. It also offers a range of third-party medical devices and technologies. The company sells its products directly to end-user customers, as well as through independent third-party distributors in Australia, the United States, Europe, the Middle East, Asia, South America, and internationally. Ellex Medical Lasers Limited is headquartered in Adelaide, Australia.

221 Employees
Last Reported Date: 08/28/14

ellex medical lasers ltd (ELX) Top Compensated Officers

Group Chief Executive Officer
Total Annual Compensation: A$248.2K
Founder, Executive Chairman, Technical Direct...
Total Annual Compensation: A$45.0K
Vice President of Adavnced Research
Total Annual Compensation: A$180.9K
Compensation as of Fiscal Year 2014.

ellex medical lasers ltd (ELX) Key Developments

Ellex Medical Lasers Limited Reports Earnings Results for the Six Months Ended December 31, 2014; Provides Earnings Guidance for the Full Year of 2015

Ellex Medical Lasers Limited reported earnings results for the six months ended December 31, 2014. For the six months, the company reported total revenue of AUD 31,244,000 against AUD 25,465,000 a year ago. EBITDA was AUD 2,703,000 against AUD 1,403,000 a year ago. PBT was AUD 1,293,000 against AUD 654,000 a year ago. Earnings per share were 0.75 cents against 0.36 cents a year ago. Net Debt as at December 31, 2014 was AUD 2.5 million. Total sales were AUD 30.7 million against AUD 25.9 million a year ago. Net Cash Flow was AUD 1.1 million against AUD 3.4 million a year ago. Operating Cash Flows was AUD 2.6 million against AUD 1.3 million a year ago. Reported NPAT was AUD 0.8 million against AUD 0.4 million a year ago. The company expects that full year revenue and profit before tax will materially exceed the prior year.

Ellex Medical Lasers Limited Provides Earnings Guidance for the Six Months Ended December 31, 2014

Ellex Medical Lasers Limited provided earnings guidance for the six months ended December 31, 2014. For the period, the company expected to report an operating profit of about $1.3 million. The result will be a material increase from $654,000 reported for the December 2013 half-year. Group revenue is expected to be $31 million, a $5 million or 19% increase compared with the prior corresponding period. The increase in revenue is primarily attributable to strong sales globally of the company's new Ultra Q Reflex laser, which is for the treatment of vitreous floaters, initial sales of the new Integre Pro retinal laser, the lower value of the Australian dollar against the US dollar, the acquisition of the Canaloplasty glaucoma surgery business and generally increased sales demand in Australia and Asia.

Ellex Medical Lasers Limited to Report First Half, 2015 Results on Feb 23, 2015

Ellex Medical Lasers Limited announced that they will report first half, 2015 results on Feb 23, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ELX:AU A$0.32 AUD -0.015

ELX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Glaukos Corp $31.79 USD -0.53
IRIDEX Corp $7.16 USD +0.13
Lumenis Ltd $13.86 USD 0.00
STAAR Surgical Co $8.77 USD -0.29
Synergetics USA Inc $4.83 USD +0.04
View Industry Companies
 

Industry Analysis

ELX

Industry Average

Valuation ELX Industry Range
Price/Earnings 25.4x
Price/Sales 0.5x
Price/Book 0.8x
Price/Cash Flow 9.2x
TEV/Sales 0.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ELLEX MEDICAL LASERS LTD, please visit www.ellex.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.